Analyst Reco. Nektar Therapeutics

Equities

NKTR

US6402681083

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
1.085 ^USD	+1.40%		-4.82%	+92.04%

06-10	Transcript : Nektar Therapeutics Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
05-09	Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating	03-05	MT
TD Cowen Upgrades Nektar Therapeutics to Outperform From Market Perform	11-09	MT
Jefferies Upgrades Nektar Therapeutics to Hold From Underperform, Adjusts Price Target to $1 From $1.50	23-05-10	MT
Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating	23-03-06	MT
Goldman Sachs Adjusts Price Target on Nektar Therapeutics to $2 From $3, Maintains Sell Rating	23-02-27	MT
Jefferies Downgrades Nektar Therapeutics to Underperform From Hold, Adjusts Price Target to $1.50 From $3.20	23-02-24	MT
SVB Securities Adjusts Price Target on Nektar Therapeutics to $3 From $5, Keeps Market Perform Rating	23-02-24	MT
FTSE 100 Falls as Jobs Data Fuel BOE Rate Rise Bets	22-10-11	DJ
JPMorgan Downgrades Nektar Therapeutics to Underweight From Neutral	22-08-08	MT
Jefferies & Co. Assumes Nektar Therapeutics at Hold, Adjust Price Target to $4 From $12	22-05-31	MT
Oppenheimer Adjusts Nektar Therapeutics Price Target to $5 From $6, Maintains Perform Rating	22-04-20	MT
Goldman Sachs Downgrades Nektar Therapeutics to Sell from Neutral, Sets $3 Price Target	22-04-18	MT
SVB Leerink Adjusts Nektar Therapeutics' Price Target to $6 from $7, Keeps Market Perform Rating	22-04-18	MT
Mizuho Securities Adjusts Price Target on Nektar Therapeutics to $6 From $8, Maintains Neutral Rating	22-04-18	MT
Canaccord Genuity Adjusts Nektar Therapeutics' Price Target to $6 From $25, Reiterates Buy Rating	22-03-16	MT
History shows stocks can weather rate hike cycle	22-03-16	RE
SVB Leerink Adjusts Nektar Therapeutics' Price Target to $7 from $18, Keeps Market Perform Rating	22-03-15	MT
Mizuho Securities Downgrades Nektar Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $35	22-03-15	MT
Cowen Downgrades Nektar Therapeutics to Market Perform From Outperform	22-03-15	MT
Oppenheimer Downgrades Nektar Therapeutics to Market Perform From Outperform, Adjusts Price Target to $6 From $21	22-03-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Nektar Therapeutics

Equities

NKTR

US6402681083

Analyst Reco.

Filters